Navigation Links
Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
Date:8/15/2011

SAN DIEGO, Aug. 15, 2011 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today presented its financial results for the second quarter ended June 30, 2011.  In addition to the announcement of second quarter 2011 financial results, Cardium reported on the Company's near-term goals and milestones including the following:(1)

Clearance from international health authorities to initiate a planned Phase 3 registration ASPIRE clinical trial for Generx® (alferminogene tadenovec/Cardionovo™) as a non-surgical, angiogenic treatment option for patients with advanced coronary artery disease who are considering balloon angioplasty and stents or open heart bypass surgery;(2)

Submission of supplemental information related to the process for manufacturing the "market ready" Excellagen™ product candidate (conducted by Scotland-based Devro Medical Limited and U.S.-based fill/finish providers), which was a key requirement for FDA 510(k) clearance; and initiation of production of commercial supplies for its Excellagen formulated bovine Type I collagen topical gel product candidate at Devro and fill/finish providers;  (3)

Expansion of the Company's development-stage MedPodium health and wellness brand platform through the introduction of two new nutraceutical products: Cerex™ (to support cognitive function) and Alena™ (a carbohydrate blocker); and(4)

Consistent with Cardium's long-term business strategy, the Company continued to identify and review potential new innovative and capital-efficient companies, products, strategic partnerships and commercialization opportunities.  (Logo:  http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

Second Quarter 2011 Financial HighlightsFor the second quarter ended June 30, 2011, the Company reported a loss
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cardium Provides Update on Excellagen 510(K) Registration and Commercialization Plans
2. Cardium Reports on Transdel Transaction
3. Cardium Announces Market Introduction of New Alena™ Clinical Strength Carb Blocker to Expand the MedPodium Healthy Lifestyle Product Line
4. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
5. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
6. Cardium Presents First Quarter 2011 Financial Results and Reports on Near-Term Milestones
7. Cardium to Present at OneMedForum San Francisco 2011 Conference
8. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
9. Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
10. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
11. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 , Glenmark,s ... positive data in a Phase 2a proof of concept ... Glenmark Pharmaceuticals today announced that its ... antagonist, GRC 17536 has shown positive data in a ... concept study conducted on 138 patients in ...
(Date:9/17/2014)... , Sept. 17, 2014  Millions of people suffer ... disc disease. Recently the FDA approved the ... disc, an innovative implant device developed by Spinal Kinetics, which ... in neck and or arm pain. Hospital for Special Surgery ... the only hospital in New York City ...
(Date:9/17/2014)... , Sept. 17, 2014  Members of the ... Interventional Associates announced today that the enterprise ... enhance its image sharing capabilities and provide immediate ... network failures. In addition, the Dicom Systems enterprise ... disparate PACS systems to more effectively deliver the ...
Breaking Medicine Technology:Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3
... 5, 2007 - First-in-human results for,IMC-A12, a monoclonal ... targeted to IGF-1R (insulin-like,growth factor type 1 receptor), ... Society of Clinical Oncology in Chicago.,The IGF-IR is ... cancers,and transmits signals that lead to tumor cell ...
... – This,year’s American Society of Clinical Oncology ... promising new data presented regarding,Merck KGaA’s targeted ... efficacy and,versatility of this agent in both ... (mCRC) and squamous cell,carcinoma of the head ...
Cached Medicine Technology:Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 2Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 3Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 2Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 3Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 4Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 5Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 6Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 7Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 8
(Date:9/17/2014)... September 18, 2014 The global ablation ... of 9.6% from 2014 to 2019. Although mature markets ... hold larger shares in the ablation technologies market in ... the highest CAGR of 12.8% in the next five ... healthcare infrastructure, growing number of hospitals and surgical centers, ...
(Date:9/17/2014)... September 18, 2014 Recently, UWDress.com, an ... and women’s special occasion outfits, has released its 2014 ... addition, the firm has launched a big sale for ... now available at deeply discounted rates, from 15 to ... the company insists on using comfortable to wear materials. ...
(Date:9/17/2014)... A ball gown is the most formal ... full-skirted gown reaching the floor, made of luxurious fabric, ... occasion gown manufacturer and retailer, has delightedly unveiled its ... gowns are offered at discounted rates. , Most versions ... gowns are typically worn with a stole (a formal ...
(Date:9/17/2014)... IntimateRider, an inventor of classy sexual enhancement ... it has entered into a dealership agreement with new ... reason for the deal is the fact that All ... its sales potential, representatives at the mobility products firm ... latest products on the market both nationally and internationally." ...
(Date:9/17/2014)... Dr. Shalev is a Texas native, and grew ... at the University of Texas, and graduated with a Bachelors ... real passion lay in dentistry, and she went on to ... Texas Health Science Center at Houston School of Dentistry. Dr. ... of The Greater Houston Dental Society, and the Texas Dental ...
Breaking Medicine News(10 mins):Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:Fecbek.com: Ladies Can Be Elegant Enough to Draw Everyone’s Attention by Wearing Trendy Ball Gowns 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 3
... IVIG worked. Its ability to treat autoimmune diseases seemed ... immunoglobulin (IVIG) is a complex mixture of IgG antibodies ... from thousands of people, and is only FDA-approved to ... it off-label with varied success in patients with lupus, ...
... geographic convenience and the quality of services that can ... to an article// in the latest edition of the ... a developing trend towards urban centralisation of surgical services, ... care standards. ,However, this creates geographical distances ...
... The Public Works and Government Services Canada said that there ... programs this year.// ,The vaccine instead of being ... in the month of November. Dr. Sheela Basrur, Ontario's chief ... by the beginning of the flu season. Public Works buys ...
... a study conducted by Prof Bernard a senior lecturer at ... found that more number// of rural people of heart attacks ... ,Statistics show that heart disease mortality rates in rural areas ... in women than in urban areas. But the solution to ...
... Australians who have type 2 diabetes could also be at ... the latest issue of the Medical Journal of Australia.// ... Renal Impairment cO-existing with NIDDM (non-insulin dependent diabetes mellitus) - ... ever undertaken in Australian general practice. ,NEFRON examined ...
... A study in Britain has found that nearly one-third of ... purpose, due to rupture, or simply slipping off// during sex, ... ,NOP world undertook a survey of nearly 497 people for ... nearly 64% were groping in the dark about the reasons ...
Cached Medicine News:Health News:Single Sugar Enables Antibody to Treat Inflammation 2Health News:Single Sugar Enables Antibody to Treat Inflammation 3Health News:Bolster Rural Surgical Services 2
... is a rapid latex agglutination ... of Helicobacter pylori total antibodies ... in the diagnosis of infection ... is intended for use to ...
... capillary electrophoresis system is designed to ... The CAPILLARYS 2 utilizes liquid flow ... diagnostic setting. Through continuous sample feed ... narrow capillary tubes functioning concurrently, a ...
Inquire...
These Iron Control Slides make an excellent addition to your laboratory. Packed ten (10) control slides per box. Use SDL's Snap n' Stain for Iron Staining Kit alongside to save time an money mixing r...
Medicine Products: